- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07558148
OCD LIFU Target Engagement
Pilot Study to Investigate Brain Targets for Neuromodulation in Obsessive-compulsive Disorder
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Marshall Nambiar, MS
- Telefonnummer: 215-746-8901
- E-post: marshall.nambiar@pennmedicine.upenn.edu
Studieorter
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Rekrytering
- University of Pennsylvania
-
Huvudutredare:
- Katherine Scangos, MD, PhD
-
Kontakt:
- Marshall Nambiar, MS
- Telefonnummer: 215-746-8901
- E-post: marshall.nambiar@pennmedicine.upenn.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
1. Participants must be enrolled in the IRB #853085 study
The inclusion criteria for the IRB #853085 study, which are also included in this trial are:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Adults aged 18-60 years old
- Chronic OCD (5 years preceding date of enrollment), diagnosed as per the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition guidelines (DSM-5)
- Presence of obsessions, compulsions, or both time-consuming obsessions and compulsions that take more than one hour a day or cause significant distress or impairment in social, occupation, or other important areas of functioning Obsessive-compulsive symptoms that are not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication) or another medical condition
- Disturbance not better explained by the symptoms of another mental disorder listed in the DSM-5 Severe OCD symptoms, as defined by Y-BOCS I score of 28 or higher, within two weeks prior to enrollment
- Compulsions need to involve movement of the hands and/or arms so that the sleeve is able to detect participant's actions (cannot be solely mental or verbal compulsions)
- Ability to understand procedure-related instructions and to complete study assessments in English, and ability to comply with protocol requirements (e.g., procedure visits, treatment schedule, follow-up visit schedule, evaluations, etc.), in the opinion of the Principal Investigator
- Willingness and ability to provide written agreement to allow any and all forms of communication between the research team and treating clinician(s) 8 Willingness and ability to provide informed consent, in the opinion of the Principal Investigator
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
Unable to undergo MRI scan
- Presence of metallic implants or devices or tattoos
- Claustrophobia or severe anxiety
- Inability to remain still for duration of scan
- Inability to fit and wear the ATTN201 device for the entire
Exclusion criteria for IRB study #853085 include:
- Hearing loss that, in the opinion of the Principal Investigator, an audiologist, or a treating physician, is likely to affect the subject's ability to comply with all of the requirements of the study, or may affect the integrity of the study data
- Pregnancy - this is an exclusion criterion because we will be intentionally increasing anxiety in participants to evaluate optimal strategies to provoke distress and then promote relaxation
- Any past or present medical condition, disease, disorder, or injury that, in the opinion of the Principal Investigator, may reduce or hinder the subject's ability to fully comply with all study requirements for the duration of the study or may impact, compromise, or affect the integrity of the data or results of the study.
- Have a previous injury or surgery which could affect the nerve distribution
- Have nerve damage (neuropathy)
- Have a diagnosed neuromuscular disorder
- Have a pacemaker
- Have a history of skin allergies, psoriasis eczema, dermatitis, or other skin inflammation conditions
- Compulsions cannot be completely mental or verbal actions, such as repeating words, counting objects, or performing mental rituals, and cannot involve only facial muscles/actions such as blinking or staring
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: LIFU Target Engagement Group
Participants in this single experimental group will undergo a series of low-intensity focused ultrasound (LIFU) sessions to evaluate safety and target engagement. Each participant will receive active LIFU stimulation at up to three personalized corticostriatal brain targets. The study utilizes a within-subject, sham-controlled design where participants receive both active LIFU and sham (placebo) stimulation across different sessions to compare physiological and clinical responses. |
Low-intensity focused ultrasound (LIFU) will be administered using the Attune ATTN201 device.
This intervention is characterized by a multifocal approach targeting three specific subcortical regions: the subthalamic nucleus (STN), the dorsal anterior cingulate cortex (dACC), and the ventral striatum (VS+).
Unlike clinical treatment trials, this is a target-engagement pilot study where each participant receives single sessions of sonication at these specific coordinates to evaluate acute physiological and symptomatic changes.
The intervention includes a within-subject sham-controlled component, where the device is positioned identically but no ultrasound energy is delivered.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Symptom Intensity through VAS score
Tidsram: From the first visit (Visit 1) through the final visit (Visit 10), approximately 6 weeks.
|
This outcome evaluates the change in symptom intensity using Visual Analog Scales (VAS) scores.
VAS include questions regarding urges to compulse/resist compulsions and subjective units of distress (SUDs), measure the intensity of a patient's impulse to carry out or control and inhibit these compulsions, and the amount of distress they feel, and are on a scale between 0-100, where higher scores signify greater symptom severity.
|
From the first visit (Visit 1) through the final visit (Visit 10), approximately 6 weeks.
|
|
Changes in Imaging between Pre- and Post-Intervention
Tidsram: Before the first visit (Visit 1) and after the final visit (Visit 10), approximately 6 weeks
|
This outcome measure evaluates safety and efficacy through neuroimaging conducted prior to and following the intervention.
These measures are intended to assess potential effects and target engagement associated with LIFU.
Efficacy measures will include changes in MRI-derived metrics (e.g., functional connectivity and/or regional activation in predefined regions of interest associated with the stimulation target).
Safety is assessed by the presence of new or worsening structural abnormalities, including edema, hemorrhage, or tissue injury.
|
Before the first visit (Visit 1) and after the final visit (Visit 10), approximately 6 weeks
|
|
Incidence of Adverse Events Assesed by Symptom Checklist
Tidsram: Immediately after each intervention session and up to 24 hours post-intervention, assessed across the intervention period (Visits 6-9).
|
This outcome measure evaluates the incidence and severity of adverse events using a structured symptomatic checklist survey administered throughout the study period.
The checklist captures the presence, frequency, and severity of potential adverse symptoms.
Adverse events will be categorized by type, relatedness, and severity.
|
Immediately after each intervention session and up to 24 hours post-intervention, assessed across the intervention period (Visits 6-9).
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Physiological Changes Measured by EMG
Tidsram: Baseline through end of intervention period (Visits 2-9), with EMG data collected at every in-person visit, approximately 4 weeks.
|
This outcome measure evaluates changes in muscle activity using surface electromyography (EMG) recorded from the forearm during sessions.
EMG signals will be collected continuously and processed using standardized pipelines.
Metrics will include various features (e.g., SNR (dB)) over defined time windows.
Change in muscle activity will be assessed by comparing pre-sonication values to post-sonication values.
|
Baseline through end of intervention period (Visits 2-9), with EMG data collected at every in-person visit, approximately 4 weeks.
|
|
Change in Y-BOCS score after sonication
Tidsram: From the first baseline visit (Visit 1) through the final visit (Visit 10).
|
This outcome measures changes in Obsessive-Compulsive symptom severity using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), administered by a trained clinician.
Scores range from 0-40, with higher scores representing greater symptom severity.
|
From the first baseline visit (Visit 1) through the final visit (Visit 10).
|
|
Change in Acceleration Measured by IMU
Tidsram: Baseline through end of intervention period (Visits 2-9), with IMU data collected at every in-person visit, approximately 4 weeks.
|
This outcome measure evaluates changes in forearm movement amplitude using inertial measurement unit (IMU)-derived acceleration data.
Acceleration (m/s²) will be recorded continuously from a microcontroller-based IMU placed on the participant's forearm during in-person sessions and processed using standardized signal processing pipelines.
Change in movement amplitude will be assessed by comparing pre-sonication and post-sonication values.
|
Baseline through end of intervention period (Visits 2-9), with IMU data collected at every in-person visit, approximately 4 weeks.
|
|
Change in Angular Velocity Measured by IMU
Tidsram: Baseline through end of intervention period (Visits 2-9), with IMU data collected at every in-person visit, approximately 4 weeks.
|
This outcome measure evaluates changes in forearm rotational movement using inertial measurement unit (IMU)-derived angular velocity data.
Angular velocity (°/s) will be recorded continuously from a microcontroller-based IMU placed on the participant's forearm during in-person sessions and processed using standardized signal processing pipelines.
Change in rotational movement will be assessed by comparing pre-sonication and post-sonication values.
|
Baseline through end of intervention period (Visits 2-9), with IMU data collected at every in-person visit, approximately 4 weeks.
|
|
Change in Heart Rate Assessed by Photoplethysmography (PPG)
Tidsram: Baseline through end of intervention period (Visits 2-9), with PPG data collected at every in-person visit, approximately 6 weeks.
|
This outcome evaluates changes in heart rate activity using photoplethysmography (PPG) recorded during sessions.
PPG signals will be collected from sensors placed on the participant and processed using standardized pipelines.
Changes in physiological response will be assessed by comparing pre to post-sonication values.
|
Baseline through end of intervention period (Visits 2-9), with PPG data collected at every in-person visit, approximately 6 weeks.
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Katherine Scangos, MD, PhD, University of Pennsylvania
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 25-0707
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .